Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocyte progenitor cells (1037 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 139 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 12276
Sealed predictions
- NAV2 in dopamine neurons, braak-0.79 (p 0.011) → -0.76 (p 0.017)held
- NAV2 in oligodendrocytes, braak-0.80 (p 0.009) → -0.43 (p 0.244)receipt 12282
Swarm cases
receipt 12282: NAV2 in oligodendrocytes, braak
- power
- full sample -0.63 (p 0.0053, n 18), 95% CI -0.85 to -0.23. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.68 (p 0.0018, n 18). holds up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.73 (p 5.6e-4, n 18). not the mix.
- skeptic
- leave-one-out range -0.72 to -0.58, sign flips 0; without severely affected donors -0.63 (p 0.0053, n 18). robust.
- cell type
- strongest in dopamine neurons: -0.73 (p 5.9e-4, n 18) vs -0.63 in oligodendrocytes. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NAV2 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NAV2 · dopamine neurons · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.38 p 0.183 (needs p < 1.8e-4)
Receipts
loading the receipts